Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Treasury Shares (2016 - 2024)

Sangamo Therapeutics (SGMO) has 14 years of Treasury Shares data on record, last reported at $11.0 million in Q4 2024.

  • For Q4 2024, Treasury Shares rose 82.11% year-over-year to $11.0 million; the TTM value through Dec 2024 reached $11.0 million, up 82.11%, while the annual FY2024 figure was $11.0 million, 82.11% up from the prior year.
  • Treasury Shares reached $11.0 million in Q4 2024 per SGMO's latest filing, up from $6.1 million in the prior quarter.
  • Across five years, Treasury Shares topped out at $11.0 million in Q4 2024 and bottomed at $2.7 million in Q4 2020.
  • Average Treasury Shares over 5 years is $5.6 million, with a median of $5.2 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: soared 209.62% in 2020, then increased 15.43% in 2023.
  • A 5-year view of Treasury Shares shows it stood at $2.7 million in 2020, then increased by 17.52% to $3.1 million in 2021, then surged by 67.02% to $5.2 million in 2022, then grew by 15.43% to $6.1 million in 2023, then skyrocketed by 82.11% to $11.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Treasury Shares were $11.0 million in Q4 2024, $6.1 million in Q4 2023, and $5.2 million in Q4 2022.